At the San Antonio Breast Cancer Symposium (SABCS) 2024, Joyce O’Shaughnessy presented findings from the KEYNOTE-522 trial, a phase 3 study evaluating pembrolizumab in combination with chemotherapy for early-stage triple-negative breast cancer (TNBC). This exploratory biomarker analysis provided deeper insights into potential predictors of response to pembrolizumab.
Key findings include:
T-cell–inflamed gene expression profile (TcellinfGEP) was associated with improved pathologic complete response (pCR) and event-free survival (EFS) in both treatment arms.
Tumor mutational burden (TMB) correlated with better EFS in patients receiving pembrolizumab + chemotherapy but not in those receiving chemotherapy alone.
Non-TcellinfGEP biomarkers (such as stromal/EMT/TGFβ and glycolysis markers) also influenced response, highlighting the complexity of immune interactions in TNBC.
These findings reinforce the potential of biomarker-driven approaches in tailoring immunotherapy strategies for TNBC, ensuring patients receive the most effective treatment based on their tumor biology.
A big thank you to Dr. O’Shaughnessy and all the researchers involved in this critical study!
For more details, visit SABCS 2024:https://lnkd.in/gVihTcUT
